1,028 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Why Merck (MRK) is a Great Dividend Stock Right Now http://www.zacks.com/stock/news/752701/why-merck-mrk-is-a-great-dividend-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_5-752701 Feb 06, 2020 - Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.
Is Merck's Decision to Slim Down a Buying Opportunity? https://www.fool.com/investing/2020/02/06/is-mercks-decision-to-slim-down-a-buying-opportuni.aspx?source=iedfolrf0000001 Feb 06, 2020 - It wasn't a big hit with investors on Wednesday.
Merck & Co., Inc. (MRK) CEO Ken Frazier on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4321702-merck-co-inc-mrk-ceo-ken-frazier-on-q4-2019-results-earnings-call-transcript?source=feed_sector_healthcare Feb 05, 2020 - Merck & Co., Inc. (NYSE:MRK) Q4 2019 Results Conference Call February 05, 2020 08:00 AM ET Company Participants Peter Dannenbaum - VP, IR Ken Frazier - Chairman and CEO Rob Davis - CFO Dr. Roger P
Merck & Co Inc (MRK) Q4 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/02/05/merck-co-inc-mrk-q4-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Feb 05, 2020 - MRK earnings call for the period ending December 31, 2019.
Merck Announces a Big Planned Spinoff https://www.fool.com/investing/2020/02/05/merck-announces-a-big-planned-spinoff.aspx?source=iedfolrf0000001 Feb 05, 2020 - The pharma giant will form a new publicly traded company out of its women's health and biosimilars businesses, and its legacy brands.
ADP Posts Blowout +291K New Jobs for January http://www.zacks.com/stock/news/750590/adp-posts-blowout-%2B291k-new-jobs-for-january?cid=CS-ZC-FT-ahead_of_wall_street-750590 Feb 05, 2020 - Monthly private-sector payrolls from Automatic Data Processing (ADP) for January posted their highest level this morning since May 2015, to a whopping 291K new private-sector jobs having been created.
Merck's Recarbrio Gets FDA Priority Review for New Indication http://www.zacks.com/stock/news/748727/mercks-recarbrio-gets-fda-priority-review-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-748727 Feb 04, 2020 - The FDA accepts Merck's (MRK) sNDA for antibacterial injection Recarbrio and grants priority review.
Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings http://www.zacks.com/stock/news/746879/factors-setting-the-tone-for-bristol-myers-bmy-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-746879 Feb 03, 2020 - Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter results.
Merck (MRK) to Report Q4 Earnings: Is a Beat in the Offing? http://www.zacks.com/stock/news/746464/merck-mrk-to-report-q4-earnings-is-a-beat-in-the-offing?cid=CS-ZC-FT-analyst_blog|earnings_preview-746464 Feb 03, 2020 - Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven Q4 sales. However, genericization of key drugs and increased competition might have been concerns.
Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative http://www.zacks.com/stock/news/742655/pharma-stock-roundup-lly-pfe-q4-results-jnjs-coronavirus-vaccine-initiative?cid=CS-ZC-FT-analyst_blog|stock_roundup-742655 Jan 31, 2020 - Lilly (LLY), Pfizer (PFE) and Novartis (NVS) announce Q4 results.

Pages: 1234567...103

<Page 2>